- Conditions
- SCN8A Developmental and Epileptic Encephalopathy Syndrome
- Interventions
- NBI-921352, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 33
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Egg Donation
- Interventions
- Follistim, Ganirelix, Menotropins, Leuprolide, Transvaginal ultrasound guided needle aspiration of oocytes
- Drug · Procedure
- Lead sponsor
- Michigan Reproductive Medicine
- Other
- Eligibility
- 18 Years to 28 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bloomfield Hills, Michigan
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
- Interventions
- Decitabine, Iodine I 131, Recombinant thyrotropin alfa, Fludeoxyglucose F 18, Positron emission tomography
- Drug · Radiation · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Columbus, Ohio • Houston, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- Zenapax
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- Thyrogen (thyrotropin alfa for injection)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Columbus, Ohio + 1 more
- Conditions
- Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer
- Interventions
- Selpercatinib, Sodium Iodine I-131, rhTSH
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 3 more
- Conditions
- Thyroid Cancer
- Interventions
- Radioactive Iodine 124
- Radiation
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Thyroid Cancer
- Interventions
- Durvalumab (Medi4736), Radioiodine (RAI)
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Infertility
- Interventions
- AFOLIA, Gonal-f® RFF
- Drug
- Lead sponsor
- Fertility Biotech AG
- Industry
- Eligibility
- 35 Years to 42 Years · Female only
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 22
- States / cities
- Tempe, Arizona • Encino, California • Newark, Delaware + 18 more
- Conditions
- Polycystic Ovary Syndrome, Healthy, Anovulation, Hyperandrogenism
- Interventions
- Recombinant Follicle Stimulating Hormone
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 37 Years · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Thyroid Cancer
- Interventions
- Euthyroid Group
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Houston, Texas
- Conditions
- Head and Neck Cancer
- Interventions
- Valproic Acid
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
- Interventions
- Biospecimen Collection, Cobimetinib, Computed Tomography, Diagnostic Imaging, I-131 Uptake Test, Iodine I-131, Magnetic Resonance Imaging, Positron Emission Tomography, Recombinant Thyrotropin Alfa, Ultrasound Imaging, Vemurafenib
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Gulf War Illness
- Interventions
- Duloxetine, Pregabalin, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 44 Years to 70 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Temple, Texas • Waco, Texas
- Conditions
- Central Precocious Puberty
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 3 Years to 9 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Morristown, New Jersey
- Conditions
- Keloid
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- rhTSH
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Tinnitus
- Interventions
- The Inhibitor™ Tinnitus Masking Device
- Device
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Thyroid Neoplasm
- Interventions
- Valproic Acid, Liothyronine Sodium
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- Modified Release rhTSH
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
- Interventions
- 4A10
- Drug
- Lead sponsor
- Allterum Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more
- Conditions
- Thyroid Carcinoma
- Interventions
- Vemurafenib, serial 124I PET/CT, thyrotropin alpha
- Drug · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York